Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population

Hepatology Research

Volumn 47, Issue 6, 2017, Pages 522-532

  Jung, Ju Young ^a,b   Park, Sung Keun ^a   Ryoo, Jae Hong ^b   Oh, Chang Mo ^c   Kang, Jeong Gyu ^a   Lee, Jae Hon ^d,e,f   Choi, Joong Myung ^b  

^a School of Medicine   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c National Cancer Center   (South Korea)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Sungkyunkwan University   (South Korea)

Author keywords

fatty liver; heart failure; left ventricular diastolic dysfunction; left ventricular remodeling

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART VENTRICLE REMODELING; HUMAN; KOREAN (PEOPLE); LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; NONALCOHOLIC FATTY LIVER;

EID: 84994578323     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12770     Document Type: Article

References (36)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34(3): 274–85. doi:10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30
2. Younossi ZM, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9(6): 524–30.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020. Epub 2011 Mar 25
3. Ratziu V, Bellentani S, Cortez-Pinto H et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53(2): 372–84. doi:10.1016/j.jhep.2010.04.008. Epub 2010 May 7
4. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55(6): 2005–23. doi:10.1002/hep.25762
5. Park SK, Seo MH, Shin HC et al. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology 2013; 57(4): 1378–83. doi:10.1002/hep.26183
6. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13(10): 1579–84.
7. Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol 2009; 8(Suppl 1): S40–3.
8. Musso G, Gambino R, Cassader M et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011 Dec; 43(8): 617–49. doi:10.3109/07853890.2010.518623. Epub 2010 Nov 2
9. Dunn W, Xu R, Wingard DL et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008; 103(9): 2263–71. doi:10.1111/j.1572-0241.2008.02034.x. Epub 2008 Aug 5
10. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49(4): 608–12. doi:10.1016/j.jhep.2008.06.018. Epub 2008 Jul 9
11. Ekstedt M, Franzén LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4): 865–73.
12. Haring R, Wallaschofski H, Nauck M et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009; 50(5): 1403–11. doi:10.1002/hep.23135
13. Bonci E, Chiesa C, Versacci P et al. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. Biomed Res Int 2015; 2015: 213737. doi:10.1155/2015/213737. Epub 2015 Jul 26
14. VanWagner LB, Wilcox JE, Colangelo LA et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015 Sep; 62(3): 773–83. doi:10.1002/hep.27869. Epub 2015 Jun 26
15. Kim NH, Park J, Kim SH et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014; 100(12): 938–43. doi:10.1136/heartjnl-2013-305099. Epub 2014 Apr 10
16. Konstam MA, Kramer DG, Patel AR et al. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011; 4(1): 98–108. doi:10.1016/j.jcmg.2010.10.008
17. Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011; 2011: 495349. doi:10.4061/2011/495349. Epub 2011 Jun 30
18. Kane GC, Karon BL, Mahoney DW et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA 2011; 306(8): 856–63. doi:10.1001/jama.2011.1201
19. Aljaroudi W, Alraies MC, Halley C et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012; 125(6): 782–8. doi:10.1161/CIRCULATIONAHA.111.066423. Epub 2012 Jan 18
20. Cheng S, Fernandes VR, Bluemke DA et al. Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging 2009; 2(3): 191–8. doi:10.1161/CIRCIMAGING.108.819938. Epub 2009 Mar 26
21. Cheng S, Xanthakis V, Sullivan LM et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 2010; 122(6): 570–8. doi:10.1161/CIRCULATIONAHA.110.937821. Epub 2010 Jul 26
22. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123(3): 745–50.
23. Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082–90.
24. Ryoo JH, Ham WT, Choi JM et al. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci 2014; 29(7): 973–9. doi:10.3346/jkms.2014.29.7.973. Epub 2014 Jul 11
25. Park SK, Ryoo JH, Choi JM, Seo MW, Park CM. The Risk of Abdominal Obesity according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men. J Korean Med Sci 2016; 31(3): 410–6.
26. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.
27. Lee JH, Kim D, Kim HJ et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010; 42(7): 503–8.
28. Vallet-Pichard A, Mallet V, Nalpas B et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46(1): 32–6.
29. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7(2): 79–108.Epub 2006 Feb 2
30. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009 Feb; 22(2): 107–33. doi:10.1016/j.echo.2008.11.023.
31. Mathiesen UL, Franzén LE, Aselius H et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002 Jul; 34(7): 516–22.
32. Ndumele CE, Nasir K, Conceiçao RD et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol 2011; 31(8): 1927–32. doi:10.1161/ATVBAHA.111.228262. Epub 2011 May 5
33. Targher G, Bertolini L, Rodella S et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) 2008; 16(6): 1394–9. doi:10.1038/oby.2008.64. Epub 2008 Mar 27
34. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62(4): 263–71. doi:10.1016/j.jacc.2013.02.092. Epub 2013 May 15
35. Dahiya R, Shultz SP, Dahiya A et al. Relation of reduced preclinical left ventricular diastolic function and cardiac remodeling in overweight youth to insulin resistance and inflammation. Am J Cardiol 2015; 115(119): 1222–8. doi:10.1016/j.amjcard.2015.02.005. Epub 2015 Feb 12
36. Sanchez AA, Levy PT, Sekarski TJ et al. Markers of cardiovascular risk, insulin resistance, and ventricular dysfunction and remodeling in obese adolescents. J Pediatr 2015; 166(3): 660–5. doi:10.1016/j.jpeds.2014.11.012. Epub 2014 Dec 30